Related Experiment Video
Updated: Jun 20, 2026
12:03
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Novel HIV-1 therapeutics through targeting altered host cell pathways
William Coley1, Kylene Kehn-Hall, Rachel Van Duyne
1George Washington University, School of Medicine, Department of Microbiology, Immunology and Tropical Medicine, Washington, DC 20037, USA.
Expert Opinion on Biological Therapy
|September 8, 2009
Summary
Drug-resistant HIV-1 strains necessitate novel therapies. Targeting host cell factors offers a promising strategy to overcome drug resistance and inhibit viral gene expression for new anti-HIV treatments.
Area of Science:
- Virology
- Drug Discovery
- Molecular Biology
Background:
- Emerging drug-resistant HIV-1 strains pose a significant challenge to current antiretroviral therapies.
- Existing treatments primarily target viral enzymes like reverse transcriptase, protease, and integrase.
- Increased prevalence of resistant HIV-1 variants in newly infected individuals highlights the need for alternative strategies.
Purpose of the Study:
- To explore novel therapeutic strategies for combating HIV-1 drug resistance.
- To investigate the potential of targeting host cell factors in HIV-1 treatment.
- To discuss methods for inhibiting HIV-1 replication by modulating host-pathogen interactions.
Main Methods:
- Reviewing current anti-HIV drug development and clinical trials.
- Analyzing the role of host cell factors in HIV-1 replication and gene expression.
- Discussing small molecule inhibitors targeting host proteins (e.g., p53, cdk9).
- Exploring siRNA-based therapies to knockdown essential host factors (e.g., CCR5, CXCR4).
- Examining the utility of viral protein interactomes in therapeutic design.
Main Results:
- Targeting host cell factors involved in HIV-1 LTR promoter activation can inhibit viral gene expression.
- Small molecules can modulate host protein functions (p53, cdk9) to impede HIV-1 replication.
- siRNA therapies can effectively reduce essential host factors (CCR5, CXCR4) crucial for viral entry.
- Viral protein interactome analysis provides insights for designing more effective therapeutics.
Conclusions:
- Targeting host cell factors represents a viable approach to overcome HIV-1 drug resistance.
- A combination of small molecules, siRNA, and interactome-based strategies can enhance HIV-1 treatment efficacy.
- Future therapeutic development should leverage host-directed strategies and a comprehensive understanding of viral-host interactions.
More Related Videos
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:26Size and Structure of Viral Genomes
Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
01:29Immune Response Against Viral Pathogens
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...